234 related articles for article (PubMed ID: 29745014)
1. Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskott-Aldrich syndrome.
Yue Y; Shi X; Song Z; Qin J; Li J; Feng S; Liu R
Pediatr Blood Cancer; 2018 Aug; 65(8):e27092. PubMed ID: 29745014
[TBL] [Abstract][Full Text] [Related]
2. Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide in Wiskott-Aldrich Syndrome With Myeloablative Conditioning.
Sharma A; Rastogi N; Kapoor R; Chatterjee G; Yadav SP
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e230-e233. PubMed ID: 32459721
[TBL] [Abstract][Full Text] [Related]
3. Successful Reduced Intensity Conditioning Alternate Donor Stem Cell Transplant for Wiskott-Aldrich Syndrome.
Thakkar D; Katewa S; Rastogi N; Kohli S; Nivargi S; Yadav SP
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e493-e496. PubMed ID: 28859032
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
5. Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide for Hemophagocytic Lymphohistiocytosis.
Kohli S; Rastogi N; Nivargi S; Thakkar D; Katewa S; Yadav SP
J Pediatr Hematol Oncol; 2019 Apr; 41(3):e158-e160. PubMed ID: 30044345
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical Stem Cell Transplantation With Post-transplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective.
Sharma A; Rastogi N; Chatterjee G; Kapoor R; Nivargi S; Yadav SP
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1033-e1036. PubMed ID: 33306606
[TBL] [Abstract][Full Text] [Related]
7. Augmented immunosuppression and PTCY-based haploidentical hematopoietic stem cell transplantation for thalassemia major.
Vellaichamy Swaminathan V; Ravichandran N; Ramanan KM; Meena SK; Varla H; Ramakrishnan B; Jayakumar I; Uppuluri R; Raj R
Pediatr Transplant; 2021 Mar; 25(2):e13893. PubMed ID: 33111490
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide.
Shah NN; Freeman AF; Su H; Cole K; Parta M; Moutsopoulos NM; Baris S; Karakoc-Aydiner E; Hughes TE; Kong HH; Holland SM; Hickstein DD
Biol Blood Marrow Transplant; 2017 Jun; 23(6):980-990. PubMed ID: 28288951
[TBL] [Abstract][Full Text] [Related]
9. Haploidentical bone marrow transplantation in a pediatric patient with Wiskott-Aldrich syndrome. A case report.
Pury S; López Orozco M; Pichichero G; Sasia LV; Morell D; Álvarez MS; Basquiera AL; Mas ME; Salvucci K
Arch Argent Pediatr; 2024 Feb; 122(1):e202310061. PubMed ID: 37471507
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
11. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
12. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ
Balashov D; Laberko A; Shcherbina A; Trakhtman P; Abramov D; Gutovskaya E; Kozlovskaya S; Shelikhova L; Novichkova G; Maschan M; Rumiantsev A; Maschan A
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1432-1440. PubMed ID: 29550630
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immune Deficiency Disorders in Children: Challenges and Outcome from a Tertiary Care Center in South India.
Uppuluri R; Sivasankaran M; Patel S; Swaminathan VV; Ramanan KM; Ravichandran N; Ramakrishnan B; Jayakumar I; Vaidhyanathan L; Raj R
J Clin Immunol; 2019 Feb; 39(2):182-187. PubMed ID: 30778805
[TBL] [Abstract][Full Text] [Related]
14. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
[TBL] [Abstract][Full Text] [Related]
15. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
16. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
17. HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide.
Sugita J
Int J Hematol; 2019 Jul; 110(1):30-38. PubMed ID: 31104211
[TBL] [Abstract][Full Text] [Related]
18. HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
Pawlowska AB; Cheng JC; Karras NA; Sun W; Wang LD; Bell AD; Gutierrez L; Rosenthal J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):185-189. PubMed ID: 28939451
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
20. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
